Medicenna Therapeutics Corp (MDNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNA) has a cash flow conversion efficiency ratio of -0.482x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-4.94 Million ≈ $-3.57 Million USD) by net assets (CA$10.24 Million ≈ $7.41 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medicenna Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MDNA total debt and obligations for a breakdown of total debt and financial obligations.
Medicenna Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicenna Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Drax Group PLC
LSE:DRX
|
0.144x |
|
Hidropar Hareket Kontrol Teknolojileri Merkezi Sanayi ve Ticaret A.S.
IS:HKTM
|
-0.323x |
|
Xiabuxiabu Catering Management (China) Holdings Co. Ltd
F:0XI
|
0.356x |
|
Xilio Development Inc
NASDAQ:XLO
|
2.161x |
|
Environmental Clean Technologies Ltd
AU:ECT
|
-1.178x |
|
Harn Engineering Solutions Public Company Limited
BK:HARN
|
0.032x |
|
Advance Zinctek Ltd
AU:ANO
|
0.024x |
|
Inzi Display Co.Ltd
KQ:037330
|
0.157x |
Annual Cash Flow Conversion Efficiency for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medicenna Therapeutics Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see MDNA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | CA$19.09 Million ≈ $13.81 Million |
CA$-16.49 Million ≈ $-11.93 Million |
-0.864x | +72.43% |
| 2024-03-31 | CA$5.19 Million ≈ $3.76 Million |
CA$-16.26 Million ≈ $-11.76 Million |
-3.132x | -629.72% |
| 2023-03-31 | CA$29.49 Million ≈ $21.33 Million |
CA$-12.66 Million ≈ $-9.16 Million |
-0.429x | +62.08% |
| 2022-03-31 | CA$20.84 Million ≈ $15.07 Million |
CA$-23.58 Million ≈ $-17.06 Million |
-1.132x | -182.01% |
| 2021-03-31 | CA$38.15 Million ≈ $27.59 Million |
CA$-15.31 Million ≈ $-11.08 Million |
-0.401x | -62.04% |
| 2020-03-31 | CA$36.15 Million ≈ $26.15 Million |
CA$-8.95 Million ≈ $-6.48 Million |
-0.248x | +91.94% |
| 2019-03-31 | CA$2.62 Million ≈ $1.89 Million |
CA$-8.04 Million ≈ $-5.81 Million |
-3.072x | +34.41% |
| 2018-03-31 | CA$2.16 Million ≈ $1.56 Million |
CA$-10.12 Million ≈ $-7.32 Million |
-4.683x | -326.75% |
| 2017-03-31 | CA$6.66 Million ≈ $4.82 Million |
CA$-7.31 Million ≈ $-5.28 Million |
-1.097x | +4.17% |
| 2016-03-31 | CA$2.24 Million ≈ $1.62 Million |
CA$-2.57 Million ≈ $-1.86 Million |
-1.145x | -102.51% |
| 2015-03-31 | CA$-19.30K ≈ $-13.96K |
CA$-880.32K ≈ $-636.81K |
45.603x | +1865.98% |
| 2014-03-31 | CA$-267.05K ≈ $-193.18K |
CA$-619.44K ≈ $-448.09K |
2.320x | -- |
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more